Stock BIO.B BIO-RAD LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Bio-Rad Laboratories, Inc. Nyse

Equities

BIO.B

US0905721082

Market Closed - Nyse
Other stock markets
 01:45:00 11/05/2024 am IST 		5-day change 1st Jan Change
279.9 USD 0.00% Intraday chart for Bio-Rad Laboratories, Inc. 0.00% -12.71%
08/05 UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating MT
08/05 RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
MT
RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420
MT
Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365
MT
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
RE
Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline
MT
Transcript : Bio-Rad Laboratories, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, vs. Street Est of $620.1M
MT
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 EPS $2.29, vs. Street Est of $2.14
MT
Bio-Rad: Q1 Earnings Snapshot
AQ
Bio-Rad Reports First-Quarter 2024 Financial Results
BU
Bio-Rad Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Bio-Rad's Management to Participate in Fireside Chat during RBC Capital Markets Global Healthcare Conference
AQ
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
BU
Bio-Rad Announces Life Science Group Management Changes
AQ
RBC Capital Adjusts Price Target on Bio-Rad Laboratories to $420 From $474
MT
Bio-Rad Announces Life Science Group Management Changes
BU
Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group
CI
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
BU
Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322
MT
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. BIO.B Stock
  5. News Bio-Rad Laboratories, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW